Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8528861 | Current Opinion in Pharmacology | 2016 | 9 Pages |
Abstract
Chronic inflammation associated with obesity is now recognized to be an important condition in promoting carcinogenesis and progression in breast cancer patients, mostly in postmenopausal women with tumors expressing estrogen and progesterone receptors. In obese patients, altered levels of several inflammatory mediators regulating aromatase and estrogen expression are one of the mechanisms responsible of increase breast cancer risk. Growing attention has also been paid to the local adipose inflammation and the role played by macrophages as determinants of breast cancer risk recurrence and prognosis. The inflammation-obesity axis offers different molecular signaling pathways for therapeutic interventions and potential pharmacological targets. The increasing rate of obesity worldwide associated with the recent findings linking inflammation and breast cancer urge further investigation.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Elisa Crespi, Giulia Bottai, Libero Santarpia,